Cyteir is currently conducting a Phase 1/2 study of CYT-0851 in B-Cell malignancies and advanced solid tumors. CYT-0851 is a potent and oral investigational drug that is designed to inhibit the RAD51-mediated homologous recombination for the repair of doublestrand DNA (dsDNA) breaks. Cancer cells require homologous recombination for the error-free repair of dsDNA breaks, the most harmful and difficult type of DNA damage to repair. Inhibiting this nonredundant DNA repair pathway drives synthetic lethality in cancer cells that are dependent on homologous recombination for surivival.
More information on the trial and enrolling sites can be found at www.clinicaltrials.gov.